In the United States marijuana is still listed under Schedule I of the Controlled Substances Act. However, the federal Food and Drug Administration (FDA) has authorized clinical trials on a CBD-based drug that treats childhood-onset epilepsy. CBD oil also shows promise in treating intestinal conditions as well as anxiety, post-workout aches, inflammation, and some types of cancers. Additional conditions are neurological inflammation, oxidative injury, and schizophrenia.
All of the product reviews listed on this website are real reviews from real users. Recommended brands are selected solely based on merit. Our vetting process includes analysis of product quality based on third party lab reports, customer service quality and responsiveness, industry reputation, company longevity and customer feedback. Per FTC guidelines, we do participate in the affiliate programs of some but not all of the recommended brands whereby we receive a small commission on purchases made through links on this website. Any references to third party products, prices or websites referenced in this group are subject to change without notice.
New name. New label. Same great formula. Bluebird Botanicals: Classic Hemp Blend contains 250 mg of concentrated CBD in a 1 oz bottle and twice that in a 2 oz bottle. Powerful, potent and tasty, this simple-to-use CBD oil soothes the senses and enhances overall wellness. The virgin hemp seed oil that holds it all together is rich in antioxidants and essential fatty acids, and its wholesome and hempy taste is perfectly balanced. This CBD-rich hemp oil blends seamlessly with hemp seed oil to create a mouth-watering, earthy flavor that goes exceptionally well with hot beverages, as well as cold drinks and a variety of foods. The rosemary extract used in this full-spectrum recipe acts as a natural preservative to ensure freshness. The end result will delight even the most discerning CBD oil fans.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×